Report of Foreign Issuer (6-k)
January 09 2020 - 7:12AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
6-K
REPORT OF FOREIGN PRIVATE
ISSUER PURSUANT TO RULE 13a-16
OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT
OF 1934
For the month of January 2020
Commission
File Number: 001-36582
Auris
Medical Holding Ltd.
(Exact name of registrant as specified in
its charter)
Clarendon House, 2 Church Street
Hamilton HM 11, Bermuda
(Address
of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes ☐ No ☒
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes ☐ No ☒
As previously disclosed, on October 11, 2019,
Auris Medical Holding Ltd. (the “Company”) announced positive interim results from its Phase 1b trial with AM-201 in
antipsychotic-induced weight gain and somnolence. The study demonstrated good safety and tolerability of AM-201 over the four-week
treatment period and revealed relevant reductions in olanzapine-induced weight gain and daytime sleepiness. In female study participants,
who overall showed more pronounced changes than male participants, a reduction in weight gain of 1.1 kg against placebo was observed
at the highest tested dose of 20 mg three times per day (probability of effectiveness = 90%).
The study has proceeded to the next higher and
final dose level of 30 mg to be tested on a cohort of 30 healthy volunteers. The Company anticipates a data read-out from the second
cohort early in the second quarter of 2020.
INCORPORATION
BY REFERENCE
This Report on Form 6-K shall be deemed to be
incorporated by reference into the registration statements on Form F-3 (Registration Number 333-228121)
and Form S-8 (Registration Number 333-232735) of Auris Medical Holding Ltd. and to be a part thereof
from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
Auris Medical Holding
Ltd.
|
|
|
|
By:
|
/s/
Thomas Meyer
|
|
|
Name:
|
Thomas Meyer
|
|
|
Title:
|
Chief Executive Officer
|
Date: January 9, 2020
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Apr 2024 to May 2024
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From May 2023 to May 2024